Skip to main content
Midas Edge

Tyra Biosciences, Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

TYRA$21.00-5.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Statements of Stockholders' Equity

(in thousands, except share amounts)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 202343,024,634$4$368,707$381$(164,830)$204,262
Issuance of common stock under Private Placement, net of issuance costs of $0.2 million9,286,0231120,557——120,558
Issuance of pre-funded warrants, net of issuance costs of $0.2 million——79,022——79,022
Issuance of common stock under benefit plans135,972—484——484
Vesting of shares of common stock subject to repurchase27,904—17——17
Stock-based compensation——4,115——4,115
Unrealized loss on marketable securities available-for-sale, net———(387)—(387)
Net loss————(18,192)(18,192)
Balance at March 31, 202452,474,533$5$572,902$(6)$(183,022)$389,879
Issuance of common stock under benefit plans246,887—624——624
Vesting of shares of common stock subject to repurchase15,038—9——9
Stock-based compensation——4,411——4,411
Unrealized loss on marketable securities available-for-sale, net———(178)—(178)
Net loss————(18,702)(18,702)
Balance at June 30, 202452,736,458$5$577,946$(184)$(201,724)$376,043
Issuance of common stock under benefit plans121,153—743——743
Vesting of shares of common stock subject to repurchase14,214—9——9
Stock-based compensation——7,573——7,573
Unrealized gain on marketable securities available-for-sale, net———1,936—1,936
Net loss————(24,016)(24,016)
Balance at September 30, 202452,871,825$5$586,271$1,752$(225,740)$362,288

Condensed Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · TotalStockholders’Equity
. · Shares · Amount
Balance at December 31, 202450,749,945$5$593,687$770$(251,311)$343,151
Issuance of common stock pursuant to pre-funded warrant exercise2,000,069—————
Issuance of common stock under benefit plans335,626—2,187——2,187
Vesting of shares of common stock subject to repurchase4,317—3——3
Stock-based compensation——6,422——6,422
Unrealized loss on marketable securities available-for-sale, net———(82)—(82)
Net loss————(28,147)(28,147)
Balance at March 31, 202553,089,957$5$602,299$688$(279,458)$323,534
Issuance of common stock under benefit plans143,537—583——583
Stock-based compensation——6,380——6,380
Unrealized loss on marketable securities available-for-sale, net———(252)—(252)
Net loss————(28,098)(28,098)
Balance at June 30, 202553,233,494$5$609,262$436$(307,556)$302,147
Issuance of common stock under benefit plans84,704—647——647
Stock-based compensation——7,577——7,577
Unrealized gain on marketable securities available-for-sale, net———6—6
Net loss————(29,868)(29,868)
Balance at September 30, 202553,318,198$5$617,486$442$(337,424)$280,509
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.